Rheumatology

Opioid Prescription Delays DMARD Initiation

by U.S. Medicine

October 14, 2018

STATESBORO, GA—What factors can cause delays in initiation of initial disease-modifying antirheumatic drug, or DMARD, in patients newly diagnosed with rheumatoid arthritis (RA)?

A retrospective cohort descriptive study used administrative data from the TRICARE program from 2007 to 2012 to help answer that question. Results were published in Seminars in Arthritis & Rheumatism.1

Georgia Southern University-led researchers identified incident RA cases using billing codes and initial DMARD receipt using prescription fill date. The study team, which also included members from the Uniformed Services University of the Health Sciences, quantified the time between RA presentation and initial DMARD receipt, analyzed changes in delay over the study period and investigated predictors of treatment delay of more than 90 days) using logistic regression.

Results indicated that the mean time from initial RA presentation to first DMARD prescription receipt was 125.3 days (SD 175.4) among 16,680 patients, mean age 47.2, with incident RA for which DMARDs were prescribed.

More than one-third, 35.6%, of the patients initiated DMARD more than 90 days after diagnosis, although treatment delay declined over the study period—mean days to DMARD was 144.7 days in 2007 but dropped to 109.7 days by 2012.

Researchers reported that patients prescribed opioids had mean time to DMARD of 212.8 days (SD 207.4) compared to mean of 77.3 days (SD 132.3) for those who did not use the painkillers. Furthermore, they noted, patients prescribed opioids between RA presentation and initial DMARD receipt were more likely to have delay in initial DMARD (OR 4.07, 95% CI: 3.78–4.37).

“In this large U.S. nationwide study, delays in initial DMARD receipt for incident RA were common but time to treatment improved in recent years, study authors concluded. “While further analysis using clinical data is warranted, these findings suggest that limiting opioid use in patients newly presenting with RA may decrease delay in initiating DMARDs.”

1. Kimsey L, Weissman JS, Patel A, Drew A, Koehlmoos T, Sparks JA. Delay in initiation of DMARD or anti-inflammatory therapy in patients newly diagnosed with rheumatoid arthritis: An analysis of United States Military Health System TRICARE beneficiaries. Seminars in Arthritis & Rheumatism. Available online 18 July 2018 https://doi.org/10.1016/j.semarthrit.2018.07.003


Comments are closed here.


Related Articles

HIV Patients Had Lower PC Incidence in VA Study

NEW YORK—Non-AIDS defining cancers are increasingly important contributors to health outcomes for aging persons with HIV (PWH), according to a recent conference presentation which also pointed out that, although prostate cancer is prevalent in aging... View Article

VA Study Finds No Link Between ADT, Dementia

LA JOLLA, CA—Research has been conflicting on whether androgen deprivation therapy is related to dementia. A research letter in JAMA Oncology pointed out that two studies reported a strong statistically significant association between ADT and... View Article


U.S. Medicine Recommends


More From rheumatology

Rheumatology

Target Lung Disease to Improve Rheumatoid Arthritis Survival

A recent VA study emphasized the importance of targeting comorbid lung disease to improve long-term outcomes in rheumatoid arthritis (RA).

Rheumatology

RA Fracture Risk Affected by Glucocorticoid Treatment

How much does systemic glucocorticoid exposure increase fracture among patients with newly-diagnosed inflammatory and immune-modulated conditions, including rheumatoid arthritis.

Rheumatology

Obesity, Weight-Loss Both Worsen RA U.S. Medicine

Obese patients with rheumatoid arthritis report greater disability in cross-sectional studies, but what that means over the long term has not been studied often.

Rheumatology

Not Enough Veterans Get Folic Acid With Methotrexate

SAN FRANCISCO—Co-prescription of folic acid in patients receiving low dose oral methotrexate (MTX) is recommended because it reduces adverse events and prolongs the use of the drug. A study on PLOS One suggests, however, that... View Article

Rheumatology

PsA Patients Not at Increased Risk of Mortality, Except for Suicide

PHILADELPHIA—What are the common causes of mortality in patients with psoriatic arthritis (PsA) compared with the general population and compared with patients with rheumatoid arthritis (RA)? A report in the journal Rheumatology (Oxford) provided some... View Article

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up